Form 4: Cullinan Therapeutics CSO Sells Shares for Tax Obligations

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 416 shares of common stock at $12.03 per share to cover tax obligations related to restricted stock unit vesting.

Summary

• Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), reported a sale of common stock.
• The transaction involved 416 shares of common stock sold at a price of $12.03 per share.
• The sale, dated February 12, 2026, was executed to cover personal income tax obligations arising from the vesting of restricted stock units.
• This transaction was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, Ms. Michaelson beneficially owns 128,219 shares of Cullinan Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, pre-planned sale for tax purposes, which does not reflect a change in the company's fundamentals or management's outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider sales executed to cover personal income tax obligations upon the vesting of restricted stock units, especially when conducted under a Rule 10b5-1 plan, are routine and generally not indicative of management's sentiment regarding the company's future prospects or a change in its operational outlook. Such transactions are a common part of executive compensation and tax planning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, pre-planned transaction for tax purposes and not indicative of a change in company performance or management's confidence.

Key Dates

Recommendation

The transaction is a routine sale to cover tax obligations upon RSU vesting and was executed under a Rule 10b5-1 plan. This type of insider activity typically does not alter the investment thesis or reflect a change in the company's fundamentals, thus maintaining a 'hold' recommendation.

Keywords

Cullinan Therapeutics, CGEM, Form 4, Insider Transaction, Stock Sale, Tax Obligations, Restricted Stock Units, RSU, Rule 10b5-1